Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
Year: 2022
Type: article
Source: Blood
Authors: Rebecca Silbermann, Jacob Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Katharine S. Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, Dana-Farber Cancer Institute, Emory University Hospital, Winship Cancer Institute, University of Utah, Huntsman Cancer Institute, University of North Carolina at Chapel Hill, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Alabama at Birmingham Hospital, The University of Texas Southwestern Medical Center, City Of Hope National Medical Center, City of Hope, University of California, San Francisco, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Nebraska Medical Center, University of California San Diego, Moores Cancer Center, University of Chicago Medical Center, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, University of Washington, Janssen Research & Development (United States), Janssen Scientific Affairs (United States), Memorial Sloan Kettering Cancer Center, Atrium Health Wake Forest Baptist, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310106513